A Study Of Transcutaneous Monitor To Predict The Onset Of Necrotizing Enterocolitis In Neonates

Overview

About this study

The aim of this minimal risk, proof-of-concept study is to determine whether machine learning-enabled, transcutaneous monitoring of neonates at high risk for NEC is safe, effective, and feasible in predicting the later onset of clinically diagnosed NEC.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Gestational age at birth 22-29 completed weeks gestation and birth weight <1500 grams.

Exclusion Criteria:

  • Known or suspected major anomalies.

  • Prior or existing diagnosis of acquired gastrointestinal disease.

  • Known or suspected skin injury or particular susceptibility to injury.

  • Admitted for or transitioned to comfort measures only.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/4/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Carey

Open for enrollment

Contact information:

William Carey

(507) 266-9397

carey.william@mayo.edu

More information

Publications

Publications are currently not available